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 Abstract 
  Background:   Alzheimer’s disease (AD) is a progressive neurodegenerative disorder. In AD, 
monocytes migrate across the blood-brain barrier and differentiate into microglia, are linked to 
inflammatory responses and display age-dependent decreases in telomere lengths.   Methods:  
Six monocyte-specific chemokines and the (telomere-associated) tumor suppressor proteins 
p53 and p21 were determined by multiplex immunoassay in plasma and monocyte extracts of 
patients with AD or mild cognitive impairment, and levels were compared between patients 
and controls (without cognitive impairment).   Results:   CCL15 (macrophage inflammatory pro-
tein-1    ), CXCL9 (monokine-induced by interferon-    ) and p21 levels were decreased in mono-
cytes of AD patients compared with controls.  Conclusion:  The combination of monocytic CCL15 
and p21 together with the Mini-Mental State Examination enables to differentiate AD patients 
from controls with high specificity and sensitivity.    Copyright © 2011 S. Karger AG, Basel 
  Published online: October 6, 2011 
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 Introduction 
  Alzheimer’s disease (AD) is a neurodegenerative disorder morphologically character-
ized by   -amyloid (A  ) plaque formation, tau pathology, neurodegeneration and inflamma-
tory processes   [1, 2]  . A probable diagnosis of AD is currently based on clinical evaluation, 
laboratory tests and brain imaging   [3]  . In order to support and simplify the diagnostic pro-
cedure, an intense search is underway for disease-specific biomarkers in the cerebrospinal 
fluid (CSF), blood plasma and blood cells. In the CSF, three biomarkers (A   42  , total tau and 
phospho-tau-181) have been well established   [4, 5]  . In blood, no specific biomarkers have 
been found despite intense research in proteins and genes of blood cells   [6]  .
  Monocytes are formed in the bone marrow and are continuously released into the blood 
  [7]  . They are involved in peripheral immune and inflammatory mechanisms, and in re-
sponse to inflammatory stimuli monocytes are recruited to the AD brain  [8–10] . Inflamma-
tory processes are abundantly found in AD, resulting in impaired regulation of several cy-
tokines and chemokines in the blood   [11, 12]  . Chemokines are produced by a wide range of 
cell types, including monocytes, and have been found to be altered in AD. Reports on in-
flammatory cytokine and chemokine levels in the plasma and serum of AD patients vary 
significantly . For example, enhanced levels of interleukin-6, tumor necrosis factor-     or 
CCL15 [macrophage inflammatory protein (MIP)-1    ] have been found   [13–15]  . While other 
studies report decreased or unchanged protein levels  [16, 17] , CXCL9 [monokine-induced by 
interferon      (MIG)] is enhanced in the plasma of AD patients   [18]  . CCL2 [monocyte che-
moattractant protein (MCP)-1] is also increased in serum and brain tissue, but it is reduced 
in peripheral blood mononuclear cells (PBMCs)  [19–21] . It has been reported that monocytes 
produce CCL2 in response to A       [22, 23]  . Moreover, in AD patients microglia display repli-
cative senescence earlier than in non-demented individuals, which may contribute to A    
plaque formation   [24, 25]  . AD patients also show shorter telomere lengths in monocytes 
compared with controls, and it is well known that a critical telomere length can trigger DNA 
damage, which is directly linked to the upregulation of tumor suppressor proteins p53 and 
p21   [26–29] .
    The aim of the present study was to investigate whether the levels of six selected spe-
cific monocyte chemokines/cytokines and the telomere-related tumor suppressor proteins 
p53 and p21 differ between patients with AD or mild cognitive impairment (MCI) and 
healthy subjects. We hypothesized that the combined statistical analysis of CCL15, p21 and 
the clinical Mini-Mental State Examination (MMSE) helps to differentiate AD patients from 
healthy controls with high sensitivity and specificity. 
  Patients  and  Methods 
  Patient Selection  
 Control (cognitively not impaired) subjects and patients suffering from AD or MCI were 
recruited from the Departments of Psychiatry in Innsbruck and Klagenfurt, Austria. All 
groups were assessed by the same diagnostic procedure. AD and MCI diagnoses were estab-
lished by a structured routine process including clinical assessment, neuropsychological 
tests (MMSE) and neuroimaging (MRI) to exclude other brain pathologies   [30]  . MCI was 
diagnosed according to the criteria of Petersen et al.  [31] . Probable AD was diagnosed accord-
ing to National Institute of Neurological and Communicative Disorders and Stroke and the 
Alzheimer’s Disease and Related Disorders Association criteria   [32]  . A general blood exam-
ination is part of the routine diagnostic procedure. All participants were scored using the 
geriatric depression scale (GDS). Exclusion criteria for healthy subjects, and MCI and AD 299
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patients included (1) another primary neurological or mental disorder (except depression, 
since it has been shown that depressive subjects without cognitive impairment were not dif-
ferent from controls in a selection of 16 plasma markers, and depressive patients with cogni-
tive impairment did also not differ from cognitively impaired patients   [15]  ), (2) any kind of 
metabolic decompensation or any sign of peripheral inflammation (e.g. rheumatic disease), 
(3) long-term alcohol or drug abuse or (4) any current, clinically significant cardiovascular 
disease. In order to test the accuracy of the laboratory examination, blood from 63 subjects 
routinely explored at the Memory Clinic (Innsbruck Medical University) was analyzed on a 
blind basis and compared with the clinical diagnosis. The study was approved by the Ethics 
Committee of Innsbruck Medical University. 
    Plasma and Monocyte Collection 
  Monocytes were isolated as described recently in detail   [33]  . Briefly, blood (10 ml) was 
collected in EDTA tubes for normal routine clinical assessment and processed within 3 h. 
Plasma and PBMCs were isolated from whole blood by centrifugation (400   g  , 30 min, room 
temperature) on a continuous-density Biocoll gradient (1.077 g/ml; Biochrom, Germany). 
Two thirds of the upper plasma phase and the interphase with the PBMCs, which is visible 
as a white stratum between the plasma phase and Biocoll, was carefully removed. Plasma was 
directly frozen at –80    °    C until use. PBMCs were washed in 50 ml of phosphate-buffered sa-
line (PBS), centrifuged at 250  g  for 6 min, and the pellet was dissolved in PBS with 1% bovine 
serum albumin. Monoyctes were isolated by negative magnetic isolation, as described by the 
manufacturer (Miltenyi Biotech, Germany). Briefly, PBMCs were incubated for 10 min on 
ice with a cocktail of various biotinylated antibodies (CD3, CD7, CD16, CD19, CD56, CD123 
and CD235a). Then anti-biotin magnetic beads were added, and the mixture was incubated 
on ice for further 15 min, washed and the cells were applied to MACS MS columns (Miltenyi 
Biotech) on a strong magnet. The non-labelled monocytes were eluted and collected. Finally, 
cells were frozen at –80    °    C until analysis.
    Measurement of Chemokines by SearchLight ELISA 
 The monocyte pellet was dissolved in 150   l PBS with a protease inhibitor cocktail (Sig-
ma, Austria), sonicated on ice (3   !   10 s, 125 W/cm  2  , 140     m amplitude, 100%) and centri-
fuged (10 min, 14,000   g ,  4   °    C). The supernatant of the monocyte extracts or plasma was used 
to detect CCL3 (MIP-1    ), CCL4 (MIP-1    ), CCL15 (MIP-1    ), CCL2 (MCP-1), CCL22 [MIP-
1   , macrophage-derived chemokine (MDC)] and CXCL9 (MIG) using the Thermo Scien-
tific SearchLight Protein Array Technology (THP Medical Products, Austria), as described 
in our recent publication   [15]  . Briefly, 50     l of calibrated protein standards or extracts were 
added to coated wells and incubated for 3 h. After washing, the biotinylated antibodies were 
added. After incubation for 30 min, the wells were washed again and incubated with strep-
tavidin-horseradish peroxidase conjugate. After the final washing step, the SuperSignal che-
miluminescent substrate was added. All incubation steps were carried out on a shaker at 
room temperature. The luminescent signal was detected using CCD imaging and a Search-
Light Array Analyst system. The concentration of each sample was quantified by comparing 
the spot intensities to the corresponding standard curves calculated from the standard sam-
ple results using the SearchLight Array Analyst Software.
    ELISA for p21 and p53 Protein 
 The p21 and p53 protein levels of monocytes and plasma were measured using commer-
cial ELISA kits (p21 Waf1/Cip1 ELISA; Invitrogen, Austria; p53 pan ELISA; Roche, Austria). 
Detection of p21 and p53 was performed as described by the manufacturer. Briefly, 100    l 
standard or extracts were added to coated wells and incubated for 2 h. After washing, the 300
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detection antibodies were added. After incubation for 1 h, the wells were washed again and 
incubated with a horseradish peroxidase conjugate for 30 min. After washing, stabilized 
chromogen substrate was added. After 30 min of incubation, the stop solution was added and 
absorbance was measured at 450 nm using a Zenyth 3100 ELISA reader.
    Statistical Analysis of Individual Markers 
  The ability of the individual markers to discriminate between diagnostic groups was 
tested by analysis of variance (ANOVA). Markers for which a significant group effect had 
been detected by ANOVA were further determined by post hoc pairwise comparisons of 
groups using Fisher’s least significant difference (LSD) method. No further adjustment for 
multiple testing was required as the number of diagnostic groups to be compared was three; 
in this case significance in the global F test and LSD testing (p  ^  0.05) was sufficient to keep 
the family-wise error rate at 0.05.
    Prediction of Group Membership by Combining Several Markers 
  Two different methods were used to predict a subject’s group membership on the basis 
of biomarkers and MMSE, namely binary logistic regression and discriminant analysis. The 
first method allows classification into only two groups, whereas the latter enables classifica-
tion into three (or more) groups. 
   Discrimination between Pairs of Groups (Healthy versus MCI/AD, Healthy/MCI versus 
AD).   Logistic regression with forward stepwise variable selection was used to identify those 
variables which, in combination, best predicted group membership in a two-group setting. 
A second analysis with backward stepwise selection served as a control (producing identical 
results). The predicted probabilities obtained from logistic regression were entered into a 
receiver-operating characteristic (ROC) analysis. From this analysis, estimates of the sensi-
tivity and specificity at various cutoff levels and of the area under the ROC curve (AUC) were 
derived. 
   Discrimination between All Three Groups.   Linear discriminant analysis with forward 
stepwise variable selection and equal a priori probabilities for all three groups (healthy, MCI 
and AD) was used for this purpose. Stepwise selection of predictor variables was based on 
Wilk’s    and the corresponding F statistic, entering all variables with a value of p  !  0.05 into 
the model. Predicted group membership was determined by means of Fisher’s linear dis-
criminant functions. Rates of correct classification and misclassification were estimated 
both directly and by means of cross-classification (bias-corrected version). In order to com-
pare prediction by laboratory data only (1) and by combining laboratory parameters with 
MMSE (2), the discriminant analysis was run twice, once for the predictor set (1) and once 
for the combination set (2), testing for improved prediction by adding MMSE.
  R e s u l t s  
 Patient  Characteristics 
 The characteristics of the patients and the controls are presented in  table 1 . As expected, 
MMSE scores differed significantly between AD patients and controls, but not between MCI 
patients and controls. Eight controls, and 23 MCI and 25 AD patients were clinically diag-
nosed with mild depression (GDS score 10–19). None of the controls, but 12 MCI and 4 AD 
patients had a diagnosis of severe depression (GDS score 20–30). Healthy controls did not 
show a significant difference in GDS scores compared with AD patients, whereas MCI pa-
tients exhibited significantly higher GDS scores than AD patients or healthy controls (  ta-
ble 1 ).301
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  Plasma  Levels 
  Chemokine plasma levels did not differ between controls and MCI patients (  table 2  ). 
Plasma levels of CCL15 and CXCL9 were significantly elevated in AD patients compared 
with controls. Plasma levels of CCL4, CCL2 and CCL22 did not differ between patients and 
controls. CCL3, p53 and p21 levels in plasma were below the limit of quantitation of the as-
say  ( table 2 ).
Table 1. P  atient characteristics
Groups n M/F Age, years MMSE GDS
Patients included for biomarker search
Control 40 19/21 72.286.3 28.581.3 6.884.4
MCI 67 23/44 73.888.0 26.982.0  11.587.8***
AD 92 21/71 78.887.1*** 18.286.1*** 8.285.3 
Patients included for the blinded study
Control 13 6/7 70.186.8 28.481.6 6.786.3
MCI 33 11/22 75.888.5* 25.682.8** 9.384.9 
AD 17 8/9 79.786.6*** 20.084.0*** 8.686.1 
M onocytes were isolated from healthy controls, and MCI and AD patients (means 8 SD). n = Number 
of samples of male/female patients (M/F). Statistical analysis was performed by one-way ANOVA with a 
Fisher LSD post hoc test. * p < 0.05; ** p < 0.01; *** p < 0.001, vs. control; the other values were nonsig-
nificant.
Table 2. C  hemokines and cytokines in plasma and monocytes
Chemokine LOQ
pg/well
Control MCI AD
Plasma 
pg/ml
CCL15, MIP-1 1.0 3,7528282 (43) 4,2838179 (91) 4,6688167 (148)**
CXCL9, MIG 0.45 1,0968168 (33) 9258164 (36) 2,5918428 (36)**
CCL3, MIP-1 1.0 <LOQ <LOQ <LOQ
CCL4, MIP-1 0.24 108812 (11) 102815 (12) 86811 (11)
CCL2, MCP-1 0.24 362821 (11) 381823 (12) 430848 (11)
CCL22, MDC 0.12 308852 (11) 212813 (12) 245832 (11)
p21 1.5 <LOQ <LOQ <LOQ
p53 15.0 <LOQ <LOQ <LOQ
Monocytes 
pg/mg
CCL15, MIP-1 1.0 15.281.5 (40) 9.280.9 (67)*** 9.980.8 (92)***
CXCL9, MIG 0.45 89815 (37) 55811 (63)* 4685 (85)**
CCL3, MIP-1 1.0 57838 (8) 3286 (8) 52817 (8)
CCL4, MIP-1 0.24 278866 (8) 210846 (8) 4728212 (8)
CCL2, MCP-1 0.24 341856 (8) 229854 (8) 5628190 (8)
CCL22, MDC 0.12 70812 (8) 124830 (8) 99835 (8)
p21 1.5 87817 (34) 80813 (48) 3284 (68)***
p53 15.0 <LOQ <LOQ <LOQ
P  lasma and monocyte chemokines, and tumor suppressors p53 and p21 were analyzed from controls, 
and AD and MCI patients using commercial ELISA and SearchLight multiplex ELISA (means 8 SEM). 
Numbers of samples analyzed are given in parentheses. LOQ = Limit of quantitation. * p < 0.05; ** p < 
0.01; *** p < 0.001, vs. control (one-way ANOVA with Fisher’s LSD post hoc test). 302
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  Monocyte  Tissue  Levels 
 In monocytes, CCL15 ( fig. 1 ) and CXCL9 levels were significantly lower in MCI patients 
than in healthy subjects (  table 2  ). In AD patients, CCL15 (  fig. 1  ), CXCL9 and p21 (  fig. 1  ) lev-
els were significantly decreased compared with controls (  table 2  ). Monocytic CCL4 and 
CCL2 displayed a tendency to an increase in AD patients. Monocytic CCL3 and CCL22 lev-
els of AD and MCI patients did not differ from those of healthy controls. The protein levels 
of p53 in monocytes were below the limit of quantitation of the assay (  table 2  ).
    Discrimination between Diagnostic Groups by Logistic Regression and ROC Analysis 
  A summary of the results of logistic regression and ROC analyses is given in   table 3  . Us-
ing monocytic biomarkers only, discrimination between controls and cognitively impaired 
subjects (either MCI or AD) was only modest. ROC analysis yielded an AUC of 0.748 in com-
  Fig. 1.   Scatter plots of CCL15 (  a  ) and p21 (  b  ) levels in monocytes of controls, MCI and AD patients. Lines 
indicate means. Sample numbers are given in parentheses.  *  *  *  p  !  0.001, vs. control; NS = Nonsignificant. 
ANOVA followed by post hoc pairwise group comparisons using Fisher’s LSD method. 
Table 3. R  esults of logistic regression and ROC analyses
Model Logistic regression ROC analysisa
significant 
predictors
model information AUC sensitivity specificity
2 d.f. p value
Prediction by laboratory data only
Control vs. MCI/AD CCL15 18.8 1 <0.0001 0.748 69.6%   72.7%
Control/MCI vs. AD p21 16.5 1 <0.0001 0.679 61.7%   61.4%
Prediction by laboratory data and MMSE
Control vs. MCI/AD CCL15, MMSE 70.1 2 <0.0001 0.912 80.7% 84.8%
Control/MCI vs. AD p21, MMSE 157.6 2 <0.0001 0.987 94.9% 93.2%
a  The cutoff value was chosen to maximize the sum of sensitivity and specificity.303
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bination with a sensitivity of 69.6% and a specificity of 72.7%. Discrimination between sub-
jects with and without AD (control/MCI) was even poorer, with a sensitivity of 61.7% and a 
specificity of 61.4% (AUC = 0.679). Considering cognitively impaired subjects only, discrim-
ination between MCI and AD was also poor (sensitivity 63.2%, specificity 64.6%, AUC 0.693, 
data not shown). Discrimination between controls and MCI/AD patients substantially im-
proved when MMSE was added to the set of predictors: sensitivity of 80.7% and specificity 
of 84.7% (AUC = 0.912). Discrimination between patients with AD and those without AD 
was even better, with sensitivity and specificity reaching values   1  90%. However, for clinical 
applications, the classification into two groups given in this subsection probably has only 
limited value. A classification of the subjects into three diagnostic groups is presented in the 
next subsection.
    Prediction of Diagnostic Group Membership by Discriminant Analysis 
 Linear discriminant analysis with stepwise variable selection and equal a priori probabil-
ities for all three groups (healthy, MCI and AD) led us to include monocytic CCL15 (step 1: 
Wilk’s      = 0.851; d.f. = 1, 2, 145; F = 11.2; p   !   0.001) and monocytic p21 (step 2: Wilk’s      = 
0.784; d.f. = 2, 2, 145; F = 9.25; p   !   0.001) in the model as significant predictors, whereas 
CXCL9 was not entered as it did not significantly improve group prediction. When MMSE 
was added as a predictor, diagnostic accuracy increased significantly (Wilk’s      = 0.346; d.f. = 
3, 2, 144; F = 33.1; p   !   0.001). Both CCL15 and p21 remained in the model as significant pre-
dictors. A summary of the classification results is shown in   table 4  . Sensitivity for the identi-
fication of MCI cases was high (81.8%). Sensitivity for the identification of AD cases was some-
what lower (72.1%), but most of the misclassified AD cases were categorized as MCI (23.7%); 
Table 4. C  lassification of results of discriminant analysis
Diagnosis Predicted group membership
healthy MCI AD
Healthy (n = 33) 19 (57.6%) 14 (42.4%) 0 (0.0%)
MCI (n = 55) 10 (18.2%) 45 (81.8%) 0 (0.0%)
AD (n = 59) 3 (5.1%) 14 (23.7%) 42 (71.2%)
Goodness of prediction (bias correction by means of cross-classification)
correct slightly misclassified 
(one category off)a
completely 
misclassifiedb 
Healthy (n = 33) 57.6% (54.5%) 42.4% (45.5%) 0% (0%)
MCI (n = 55) 81.8% (78.2%) 18.2% (21.8%) 0% (0%)
AD (n = 59) 71.2% (71.2%) 23.7% (23.7%) 5.1% (5.1%)
Total (n = 147) 72.1% (70.1%) 25.9% (27.9%) 2.0% (2.0%)
Cl assification  formulae: 
Healthy f0 = 0.01449p21 + 0.314CCL15 + 1.815MMSE – 30.174; 
MCI        f1 = 0.01352p21 + 0.171CCL15 + 1.697MMSE – 25.060; 
AD          f2 = 0.00506p21 + 0.201CCL15 + 1.153MMSE – 12.653. 
Rule: Classify as control if f0 > f1 and f0 > f2; classify as MCI, if f1 > f0 and f1 > f2; classify as AD, if 
f2 > f0 and f2 > f1. a Actual group and predicted group in adjacent categories, e.g. actual group = healthy, 
predicted group = MCI. b Actual group and predicted group are completely different, e.g. actual group = 
healthy, predicted group = AD. 304
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only 3 cases (5.1%) were erroneously classified as healthy. The specificity of the prediction 
model was only modest (57.6% correctly identified healthy controls), but all misclassified 
healthy controls were categorized as MCI, none as AD. Working with Fisher’s linear discrim-
inant functions (f0, f1, f2), the analysis yielded a formula allowing the prediction of diagnostic 
group membership on the basis of a patient’s CCL15, p21 and MMSE values (  table 4  ).
  Blinded  Laboratory  Analysis 
  In order to test the accuracy of the prediction model based on laboratory biomarkers 
and MMSE, 63 patients routinely examined at the Memory Clinic were analyzed. Based on 
the formula, our ‘laboratory diagnosis’, including CCL15, p21 and MMSE, classified 60 sub-
jects as cognitively impaired, while only 3 subjects were categorized as (cognitively not im-
paired) controls (  table 5  ). In contrast, according to the clinical diagnosis, only 50 subjects 
were classified as cognitively impaired, while 13 were defined as controls without cognitive 
impairment (  tables 1  ,   5  ). Eleven subjects were categorized as AD cases according to the 
blinded laboratory analysis, whereas the clinical examination identified 17 cases with AD 
(  table 1  ). The classification results are detailed in   tables 1   and   5  . Overall, in 63.8% of the 
subjects (43 of 63), classification did not differ between both methods; slight deviations 
(healthy subjects classified as MCI, MCI patients classified as AD patients) occurred in 
36.2% of the cases. There were no completely misclassified cases (healthy subjects classified 
as AD or vice versa). 
  Discussion 
 Our findings show significantly decreased plasma levels for two monocyte-specific che-
mokines (CCL15 and CXCL9) and a reduction in the tumor suppressor p21 in AD patients 
compared to healthy subjects. When combining these two laboratory biomarkers with a 
clinical marker (MMSE), AD patients can be differentiated from healthy controls and MCI 
with high sensitivity and specificity.
  Monocytes  and  AD 
  There is strong evidence that monocytes play a role in neuroinflammatory processes 
seen in AD. Monocytes migrate across a compromised blood-brain barrier and express che-
mokine receptors to guide immune cells to inflammatory sites  [9, 10, 34–36] . Monocytic cell 
adhesion molecules are altered in AD patients  [33, 37] . Further, the expression of chemokine 
receptors and cytokines was found to be increased in PBMCs of AD patients  [38] . Thus, po-
Table 5. D  iagnosis from blinded samples using the formulae obtained by discriminant analysis
Clinical diagnosis P  redicted diagnosis based on p21, MIP-1 and MMSE using the formulae 
healthy   (n = 3) MCI (n = 49) AD (n = 11)
Healthy (n = 13) 1 (7.7%) 12 (92.3%) 0 (0.0%)
MCI (n = 33) 2 (6.1%) 31 (93.9%) 0 (0.0%)
AD (n = 17) 0 (0.0%) 6 (35.3%) 11 (64.7%)
Blo  od from subjects routinely examined at the Memory Clinic was analyzed under ‘blinded’ condi-
tions using the three statistical formulae (see Results) including p21, CCL15 and MMSE. These data were 
subsequently compared with the clinical diagnosis.305
Dement Geriatr Cogn Disord Extra 2011;1:297–309
 DOI:  10.1159/000330468 
EXTRA
  Hochstrasser et al.: Monocyte Markers and Alzheimer’s Disease 
www.karger.com/dee
  © 2011 S. Karger AG, Basel 
  Published online: October 6, 2011 
tentially pathogenic mechanisms in AD, e.g. immune cell activation, may correlate with 
impaired regulation of cytokines, chemokines and cell adhesion molecules seen in the dis-
ease. 
    Chemokines in Monocytes and Plasma 
  This study provides additional evidence that chemokines are specifically affected in AD. 
The plasma levels of two of six chemokines, i.e. CCL15 and CXCL9, were increased. Both che-
mokines play a major role in the recruitment of immune cells to sites of injury or infection. 
CCL15 belongs to a subgroup of CC chemokines (containing six cysteine residues) and is ex-
pressed in monocytes after exposure to inflammatory stimuli   [39, 40]  . It has been shown that 
CCL15 plasma levels are reduced (  d   score –1.6) in AD patients compared to controls   [17]  . The 
present study found reduced levels of CCL15 in monocytes and higher plasma levels in patients 
suffering from AD, which is in agreement with our previous study  [15] . CXCL9 has chemotac-
tic functions and plays a role in inflammatory response modulation. It has been shown that 
CXCL9 plasma levels are higher in AD patients   [18]  , which is consistent with our present ob-
servation. Most importantly , here we show that CX CL9 levels were significantly lower in 
monocytes of AD patients than in controls. Thus, it seems likely that reduced levels of CCL15 
and CXCL9 in monocytes directly reflect an enhanced release of these cytokines into the 
blood, which fully correlates with our findings of enhanced plasma levels. However, it cannot 
be ruled out that the unchanged chemokines have a potential role in AD. CCL3 acts as a che-
moattractant for a variety of cells and is produced and released by monocytes after stimulation 
with A       [23]  . CCL4 has been isolated from monocytes, has chemotactic activity and showed 
no difference between the brains of AD patients and controls   [21, 41]  . CCL2 plays a role in the 
migration of monocytes to sites of injury and infection, is produced in microglia and can be 
stimulated by A       [22, 42]  . Overall, it has been reported that CCL2 is upregulated in the brain, 
CSF, serum and plasma of AD patients   [20, 21, 43, 44]  . However, CCL2 plasma levels were de-
creased in severe AD   [45]  . In CSF and serum, CCL2 did not differ between control, MCI and 
AD groups   [46, 47]  . Even more controversially, CCL2 levels increased with age regardless of 
AD   [48]  . CCL22 and its receptor CCR4 play a role in homeostatic and inflammatory process-
es. The high heterogeneity between different studies may be ascribed to methodological dif-
ferences, but also to the stage of disease, and the age and the overall health status of the patients.
    p21 and p53 in Monocytes and Plasma 
  We assessed monocyte and plasma levels of tumor suppressor proteins p53 and p21, since 
we discovered a reduced telomere length in monocytes of AD patients (data not shown). Both 
proteins play a critical role in cell death and aging, and are directly related to telomere dys-
function   [27–29]  . The tumor suppressor p21 is a direct target of p53 and mediates the p53-
dependent cell cycle arrest in response to DNA damage and subsequent DNA repair   [27, 49, 
50]  . In the brain, p53 plays an important role in regulating amyloid-precursor protein (APP) 
  [51]  , and APP protects neuronal cells against apoptosis by controlling p53 activation at the 
posttranslational level  [52] . Further, it has been reported that p53 inhibition prevented microg-
lial neurotoxicity   [53]  . In AD blood lymphocytes, the p53 protein and the dysfunction of the 
G  1  /S checkpoint have been considered as potential biomarkers   [54]  . Furthermore, it has been 
shown that p21-activated kinase interacts with APP and is markedly reduced in AD  [55] . Thus, 
in the present study, we measured both tumor suppressor proteins in plasma and monocytes, 
but could not detect p53. However, to our knowledge, our data show for the first time that p21 
is significantly reduced in monocytes of AD patients, which was not detectable in plasma. It 
seems likely that p21 is associated with telomere length reductions in monocytes but not se-
creted into the blood. The reduced p21 monocytic levels in AD patients could be a direct 
mechanism of the disease pathology or directly related to the telomere-shortening process. 306
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    MMSE as a Clinical Marker in Combination with Blood Markers 
  Our data show that the combination of two cytokines and the p21 suppressor protein 
alone enables neither satisfactory differentiation between cognitively impaired patients and 
healthy controls, nor a useful distinction of patients with AD from those without AD. How-
ever, when adding MMSE to the set of predictor variables, differentiation between the diag-
nostic groups was markedly improved. Notably, both MMSE and biomarkers (CCL15 and 
p21) were required to obtain a useful prediction. MMSE alone was also not sufficient. Our 
discriminant analysis based on CCL15, p21 and MMSE yielded a high sensitivity of 81.8% for 
the identification of MCI patients and a somewhat lower, but still fairly satisfactory, sensitiv-
ity of 71.2% for the correct detection of AD cases (particularly as almost all misclassified AD 
patients were categorized as MCI). Specificity levels were somewhat less satisfactory. Our al-
location method based on biomarkers and MMSE tended to classify subjects as MCI, even if 
they were diagnosed as cognitively healthy by the clinician. However, the clinical diagnosis 
may not always be correct. Sometimes subjects with minor cognitive impairments are diag-
nosed as healthy by the clinician, whereas laboratory markers have the potential to identify 
AD-associated alterations at a very early stage. 
    The MMSE is a brief 30-point questionnaire that is used to screen for cognitive impair-
ment and to estimate the severity of cognitive impairment at a given point in time. The 
MMSE total score may differentiate between normal age-associated memory symptoms and 
MCI (a possible prodromal state of AD) and also separate MCI from mild AD. As the MMSE 
was initially also used by the clinicians to diagnose AD, it seems to be a circle evidence to 
include MMSE in this type of diagnostic algorithm at first glance. We are fully aware of the 
clinical problems of an AD diagnosis, especially since the AD diagnosis is not confirmed by 
neuropathology. However, the aim of the blinded study was to receive the MMSE from the 
clinicians and to perform the blood tests, and to apply the blinded algorithm to separate AD/
MCI/controls. Based on this algorithm, it was possible to include the ‘blinded MMSE value’ 
obtained by clinicians and combine it with the two blood biomarkers. This way, the inclusion 
of MMSE was a first circle evidence marker to establish the algorithm, which could not have 
been possible without any histopathology. In order to test the efficiency of the ‘laboratory 
diagnosis’, we tested 63 subjects on a blinded basis and compared the findings with the clin-
ical diagnosis. Indeed, the diagnosis was consistent in 43 of 63 cases (63.8%). Moreover, in 
none of the cases was a subject with a clinical diagnosis of AD classified as cognitively healthy 
or vice versa. We were thus able to distinguish AD patients from controls with high sensitiv-
ity and specificity. 
    Limitations of the Study 
  This study, however, has some limitations. First, the number of subjects analyzed was 
small, although the findings were statistically significant. Due to the limited amount of 
samples, we could not perform measurements for all cytokines. Second, this was a cross-
sectional study. Therefore, it cannot be determined whether the changes in chemokine lev-
els cause the disease or are the results of brain pathology and inflammation in AD. Further 
research confirming these findings in large, prospective studies is needed. Current research 
efforts aim to identify individual markers or combinations of markers to facilitate objective 
diagnosis and treatment of AD. Changes in CCL15 and p21 levels are not proposed as a 
stand-alone test or screening tool, but they may be interesting biomarker candidates in a 
multiple-biomarker strategy. Further studies applying CCL15 and p21 together with multi-
ple-biomarker strategies as well as other clinical markers may further improve diagnostic 
accuracy for early AD, MCI and other types of dementia (e.g. frontotemporal lobe demen-
tia), too.307
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  Conclusion 
 Levels of CCL15, CXCL9 and p21 in monocytes were decreased in AD patients compared 
with healthy controls. Consequently, the combination of CCL15 and p21 with the MMSE 
enables differentiation of cognitively impaired subjects, specifically between AD patients 
and controls, with high specificity and sensitivity.
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